121 related articles for article (PubMed ID: 20048699)
1. Specificities of broadly neutralizing anti-HIV-1 sera.
Binley J
Curr Opin HIV AIDS; 2009 Sep; 4(5):364-72. PubMed ID: 20048699
[TBL] [Abstract][Full Text] [Related]
2. Challenges for structure-based HIV vaccine design.
Schief WR; Ban YE; Stamatatos L
Curr Opin HIV AIDS; 2009 Sep; 4(5):431-40. PubMed ID: 20048708
[TBL] [Abstract][Full Text] [Related]
3. Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization.
Georgiev IS; Doria-Rose NA; Zhou T; Kwon YD; Staupe RP; Moquin S; Chuang GY; Louder MK; Schmidt SD; Altae-Tran HR; Bailer RT; McKee K; Nason M; O'Dell S; Ofek G; Pancera M; Srivatsan S; Shapiro L; Connors M; Migueles SA; Morris L; Nishimura Y; Martin MA; Mascola JR; Kwong PD
Science; 2013 May; 340(6133):751-6. PubMed ID: 23661761
[TBL] [Abstract][Full Text] [Related]
4. Identification and characterization of broadly cross-reactive neutralizing antibodies in patients infected with HIV-1 B'/C recombinant (CRF07_BC).
Bao MJ; Geng WQ; Cui HL; Zhang XL; Xu DB; Nian H; Dai D; Wang YN; Shang H
Mol Med Rep; 2012 May; 5(5):1311-7. PubMed ID: 22344547
[TBL] [Abstract][Full Text] [Related]
5. Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression.
Euler Z; van Gils MJ; Bunnik EM; Phung P; Schweighardt B; Wrin T; Schuitemaker H
J Infect Dis; 2010 Apr; 201(7):1045-53. PubMed ID: 20170371
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression.
van Gils MJ; Euler Z; Schweighardt B; Wrin T; Schuitemaker H
AIDS; 2009 Nov; 23(18):2405-14. PubMed ID: 19770692
[TBL] [Abstract][Full Text] [Related]
7. Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity.
Braibant M; Brunet S; Costagliola D; Rouzioux C; Agut H; Katinger H; Autran B; Barin F
AIDS; 2006 Oct; 20(15):1923-30. PubMed ID: 16988513
[TBL] [Abstract][Full Text] [Related]
8. HIV vaccine development: challenges and opportunities towards solving the HIV vaccine-neutralizing antibody problem.
Koff WC
Vaccine; 2012 Jun; 30(29):4310-5. PubMed ID: 22100891
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 neutralizing antibodies elicited by the candidate CBD1 epitope vaccine react with the conserved caveolin-1 binding motif of viral glycoprotein gp41.
Rey-Cuillé MA; Svab J; Benferhat R; Krust B; Briand JP; Muller S; Hovanessian AG
J Pharm Pharmacol; 2006 Jun; 58(6):759-67. PubMed ID: 16734977
[TBL] [Abstract][Full Text] [Related]
10. New virologic reagents for neutralizing antibody assays.
Ochsenbauer C; Kappes JC
Curr Opin HIV AIDS; 2009 Sep; 4(5):418-25. PubMed ID: 20048706
[TBL] [Abstract][Full Text] [Related]
11. Mimotopes selected with antibodies from HIV-1-neutralizing long-term non-progressor plasma.
Humbert M; Antoni S; Brill B; Landersz M; Rodes B; Soriano V; Wintergerst U; Knechten H; Staszewski S; von Laer D; Dittmar MT; Dietrich U
Eur J Immunol; 2007 Feb; 37(2):501-15. PubMed ID: 17236253
[TBL] [Abstract][Full Text] [Related]
12. Neutralization and infectivity characteristics of envelope glycoproteins from human immunodeficiency virus type 1 infected donors whose sera exhibit broadly cross-reactive neutralizing activity.
Cham F; Zhang PF; Heyndrickx L; Bouma P; Zhong P; Katinger H; Robinson J; van der Groen G; Quinnan GV
Virology; 2006 Mar; 347(1):36-51. PubMed ID: 16378633
[TBL] [Abstract][Full Text] [Related]
13. Catch Me If You Can--The Race Between HIV and Neutralizing Antibodies.
Geiß Y; Dietrich U
AIDS Rev; 2015; 17(2):107-13. PubMed ID: 26035168
[TBL] [Abstract][Full Text] [Related]
14. Dichotomy in cross-clade reactivity and neutralization by HIV-1 sera: Implications for active and passive immunotherapy.
Cavacini LA; Duval M; Patil A; Wood C; Mayer KH; Ruprecht RM; Posner MR
J Med Virol; 2005 Jun; 76(2):146-52. PubMed ID: 15834877
[TBL] [Abstract][Full Text] [Related]
15. HIV broadly neutralizing antibody targets.
Wibmer CK; Moore PL; Morris L
Curr Opin HIV AIDS; 2015 May; 10(3):135-43. PubMed ID: 25760932
[TBL] [Abstract][Full Text] [Related]
16. What's new in HIV/AIDS? Neutralizing HIV antibodies: do they really protect?
Jülg B; Goebel FD
Infection; 2005 Oct; 33(5-6):405-7. PubMed ID: 16258878
[TBL] [Abstract][Full Text] [Related]
17. The role of neutralizing antibodies in HIV infection.
Humbert M; Dietrich U
AIDS Rev; 2006; 8(2):51-9. PubMed ID: 16848273
[TBL] [Abstract][Full Text] [Related]
18. Antigenic properties of a transport-competent influenza HA/HIV Env chimeric protein.
Ye L; Sun Y; Lin J; Bu Z; Wu Q; Jiang S; Steinhauer DA; Compans RW; Yang C
Virology; 2006 Aug; 352(1):74-85. PubMed ID: 16725170
[TBL] [Abstract][Full Text] [Related]
19. Selective recognition of oligomeric HIV-1 primary isolate envelope glycoproteins by potently neutralizing ligands requires efficient precursor cleavage.
Pancera M; Wyatt R
Virology; 2005 Feb; 332(1):145-56. PubMed ID: 15661147
[TBL] [Abstract][Full Text] [Related]
20. Antibodies that cross-neutralize the tier-2 pseudoviruses are produced in antiretroviral-naïve HIV-1-infected children from northern India.
Prakash SS; Andrabi R; Kumar R; Lodha R; Kabra SK; Vajpayee M; Luthra K
Arch Virol; 2012 Sep; 157(9):1797-801. PubMed ID: 22674340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
